✦ LIBER ✦

24 Outcomes with erlotinib (Tarceva®) in a Yorkshire cancer centre

✍ Scribed by O'Toole, L.; Bond, M.; Snee, M.

Book ID: 118573955
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 46 KB
Volume: 57
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(07)70350-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of neoadjuvant erlotini

A phase II study of neoadjuvant erlotinib (Tarceva) in patients with muscle-invasive bladder cancer undergoing radical cystectomy: Preliminary results

✍ Angela Smith; Matthew Coward; William Kim; Matthew Nielsen; Eric Wallen; Raj S. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 137 KB

A PHASE II STUDY OF NEOADJUVANT ERLOTINI

A PHASE II STUDY OF NEOADJUVANT ERLOTINIB (TARCEVA) IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER UNDERGOING RADICAL CYSTECTOMY: PRELIMINARY RESULTS

✍ Pearson, Matthew; Nix, Jeffrey; Kim, William; Grigson, Gayle; Wallen, Eric; Prut 📂 Article 📅 2008 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 124 KB

Phase III Study of Erlotinib in Combinat

Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non-Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

✍ Gatzemeier, U.; Pluzanska, A.; Szczesna, A.; Kaukel, E.; Roubec, J.; De Rosa, F. 📂 Article 📅 2007 🏛 American Society of Clinical Oncology 🌐 English ⚖ 169 KB

Phase III Study of Erlotinib in Combinat

Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non-Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

✍ Gatzemeier, U.; Pluzanska, A.; Szczesna, A.; Kaukel, E.; Roubec, J.; De Rosa, F. 📂 Article 📅 2007 🏛 American Society of Clinical Oncology 🌐 English ⚖ 169 KB

## Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase, with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of chemotherapy. This phase III, randomized, double-blind, placebo-controlled, multicenter trial evaluated th

Erlotinib (OSI-774, Tarceva™), a Selecti

Erlotinib (OSI-774, Tarceva™), a Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Chemotherapy for Advanced Non–Small-Cell Lung Cancer

✍ Mary Hightower; Chandra P. Belani; Vinay K. Jain 📂 Article 📅 2003 🏛 CIG Media Group, LP. 🌐 English ⚖ 78 KB

An expanded access program of erlotinib

An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy

✍ Tiseo, Marcello; Gridelli, Cesare; Cascinu, Stefano; Crinò, Lucio; Piantedosi, F 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 541 KB